New alpha-glucosidase inhibitors from a natural source
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A kind of technology of glucosidase, inhibitor, applied in the field of new natural source glucosidase inhibitor
Inactive Publication Date: 2005-12-14
COUNCIL OF SCI & IND RES
View PDF0 Cites 10 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Although several drugs targeted for use as α-glucosidase inhibitors are either still under clinical investigation or at various stages of clinical development (Drugs of the future 1986, 11, 79
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment Construction
[0035] According to the purpose of the present invention, the present invention provides the method for inhibiting the α-glucosidase of individual, described method is to the individual administration effective dose pharmaceutical composition, and described composition comprises and is selected from pipataline (formula 1a), sesamin Alpha-glucosidase inhibitors of (formula 1b), parittomide (formula 1c), guineensine (formula 1d) and brachystamide-B (formula 1e) and pharmaceutically acceptable ingredients, the pharmaceutical composition can be used for the treatment of individual Suffering from diseases such as hyperglycemia, hyperinsulinemia, hyperlipoproteinemia, cancer, viral infection, hepatitis B and C, HIV and AIDS.
[0036] In one embodiment of the invention, pipataline provides α-glucosidase inhibitory activity up to 77.45%, IC 50 The value was 26.52 (μg / ml).
[0037] In yet another embodiment of the present invention, sesamin provides α-glucosidase inhibitory activity u...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The present invention relates to a method for providing alpha -glucosidase inhibition to a subject by administering a pharmaceutical composition comprising a alpha -glucosidase inhibitory agent selected from pipataline (formula 1a), sesamin (formula 1b), pellitorine (Formula 1c), guineensine (Formula 1d) and brachystamide-B (formula 1e) having therapeutic application for diabetes mellitus, cancer, viral diseases such as hepatitis B and C, HIV, AIDS etc; also the invention provides a process for the isolation of said alpha -glucosidase inhibitory agent from the plant source Piper longum in significant yields.
Description
technical field [0001] The present invention relates to the method that the glucosidase of body is inhibited by administering a kind of pharmaceutical composition, and described composition comprises and is selected from , an alpha-glucosidase inhibitor of guineensine (formula 1d) and brachystamide-B (formula 1e). In particular, the present invention relates to the isolation of the above five compounds, namely, pipataline [5-(1-dodecenyl)-1,3-benzodioxolane], sesame Element [5,5-(tetrahydro-1H,3H-furo(3,4-e)furan-1,4 diyl)bis-1,3-benzodioxolane], pyritolide [ N-(2-methylpropyl)-2,4-decadienamide], guineensine[13-(1,3-benzodioxolan-5-yl)-N(2-methylpropane base)-2,4,12-tridecenylamide] and brachystamide-B[15-(1,3-benzodioxolan-5-yl)-N(2-methylpropyl)- 2,4,14-Pentadecenetrienamide]. The present invention also finds that such compounds are used as α-glucosidase inhibitors, and used in the form of suitable pharmaceutical compositions for treating diabetes, cancer, and viral dis...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more